ArticleMedicine2018
Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Uterine sarcoma: A 10-year retrospective analysis of clinicopathological and prognostic factors of surgically treated cases.Ecancermedicalscience · 2026Article
- Article
- A lactate related signature for predicting prognosis and tumor microenvironment in lung adenocarcinoma.Discover oncology · 2025Article
- Artificial Intelligence and Uterine Fibroids: A Useful Combination for Diagnosis and Treatment.Journal of clinical medicine · 2025Review
- The value of multiparametric MRI-based habitat imaging for differentiating uterine sarcomas from atypical leiomyomas: a multicentre study.Abdominal radiology (New York) · 2025Article
- Article
- Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.BMC cancer · 2024Article
- Enzymes as indispensable markers in disease diagnosis.Bioanalysis · 2024Review
- Article
- Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma.BMC cancer · 2023Article
- Development of an Algorithm to Differentiate Uterine Sarcoma from Fibroids Using MRI and LDH Levels.Diagnostics (Basel, Switzerland) · 2023Article
- Sonographic and Magnetic Resonance Characteristics of Gynecological Sarcoma.Diagnostics (Basel, Switzerland) · 2023Review
- Key therapeutic targets implicated at the early stage of hepatocellular carcinoma identified through machine-learning approaches.Scientific reports · 2023Article
- Understanding the Contribution of Lactate Metabolism in Cancer Progress: A Perspective from Isomers.Cancers · 2022Review
- Review
- New Aspects of Sarcomas of Uterine Corpus-A Brief Narrative Review.Clinics and practice · 2021Review
- Vascular biology of uterine fibroids: connecting fibroids and vascular disorders.Reproduction (Cambridge, England) · 2021Review
- Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.Cancer management and research · 2021Article
- Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid.BMC cancer · 2020Article
- The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to determine the expression of lactate dehydrogenase (LDH)-A and LDH-D in patients with uterine myoma, cellular leiomyoma (CLM), and uterine sarcoma and to evaluate their prognostic significance.
methodsProtein expression levels of LDH-A and LDH-D were determined in tissue samples from 86 patients (26 uterine myoma, 10 CLM, 50 uterine sarcoma) by immunohistochemistry and their associations with clinicopathologic parameters and outcomes were analyzed in patients with uterine sarcoma.
resultsThe positivity rates for LDH-A and LDH-D were significantly higher in patients with uterine sarcoma compared with those with uterine myoma or CLM (P < .05). Patients with uterine sarcoma were classified as having uterine leiomyosarcoma (LMS), malignant endometrial stromal sarcoma, and malignant mixed Mullerian tumor, with 5-year overall survival rates of 59%, 71%, and 29%, respectively (P < .05). Univariate analysis showed that patients younger than 50 years and with stage I-II had better clinical prognoses. LDH-A-positive LMS patients had a poorer prognosis than LDH-A-negative patients (P = .03). The median survival time of LDH-A-positive patients was 35 months.
conclusionsWe demonstrated that LDH-D was expressed in patients with uterine sarcoma. Furthermore, the overexpressions of LDH-A and LDH-D in uterine sarcoma patients may contribute to further understanding of the mechanism of LDH in tumor metabolism in uterine sarcoma. Positive expression of LDH-A in patients with LMS may act as a potential prognostic biomarker in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.